Introduction to Refractory Classic
Sentence Examples
Discover more insights into Refractory Classic
Keywords frequently search together with Refractory Classic
Narrow sentence examples with built-in keyword filters
Refractory Classic sentence examples within lymphoma r r
This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results.
Full Text
7530 Background: Clinical trials of novel salvage therapies (ST) have encouraging outcomes for relapsed/refractory classic Hodgkin lymphoma (R/R cHL) eligible for autologous stem cell transplant (ASCT).
Full Text
Refractory Classic sentence examples within programmed death 1
PURPOSE
Anti-programmed death-1 (PD-1) monotherapy induces a high response rate in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but complete remission (CR) is infrequently observed.
Full Text
PURPOSE
Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL).
Full Text
Refractory Classic sentence examples within high dose chemotherapy
For patients who experience relapse or refractory classical Hodgkin lymphoma, the standard treatment option is high-dose chemotherapy followed by autologous stem cell rescue or transplant.
Full Text
In case of relapsed and refractory classical Hodgkin lymphoma (r/r cHL), second-line treatment and high-dose chemotherapy with autologous stem cells transplantation (ASCT) allow to achieve a sustained remission in half of the patients while the failure of ASCT defines poor prognosis [2,3].
Full Text
Learn more from Refractory Classic
Refractory Classic sentence examples within stem cell transplantation
BACKGROUND
Relapsed or refractory classical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stem-cell transplantation.
Full Text
Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory classical Hodgkin lymphoma (RR cHL) who respond to salvage chemotherapy.
Full Text
Refractory Classic sentence examples within autologous stem cell
The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT).
Full Text
e19516 Background: There are few optimized therapeutic options for relapsed and/or refractory classic Hodgkin’s lymphoma (r/rCHL), especially in patients who failed in treatments of autologous stem cell transplantation (ASCT), brentuximab vedotin or even immune checkpoint blockage.
Full Text
Refractory Classic sentence examples within Medically Refractory Classic
Methods: We prospectively recruited 14 medically refractory classical TN patients and 20 healthy subjects.
Full Text
Methods
We prospectively recruited 22 medically refractory classic or idiopathic TN patients undergoing surgical treatment over a 3-year period, and 19 age- and sex-matched healthy control subjects.
Full Text
Refractory Classic sentence examples within refractory classic hodgkin
Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL).
Full Text
Introduction Brentuximab vedotin (BV) and the PD-1 inhibitors, pembrolizumab and nivolumab, have dramatically improved therapeutic options in relapsed and refractory classic Hodgkin.
Full Text
Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin’s lymphoma.
Full Text
Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL).
Full Text
Introduction Brentuximab vedotin (BV) and the PD-1 inhibitors, pembrolizumab and nivolumab, have dramatically improved therapeutic options in relapsed and refractory classic Hodgkin.
Full Text
e19515 Background: The anti-PD-1 combination therapy significantly improves clinical outcomes in patients with relapsed/refractory classical Hodgkin lymphoma (cHL), and up to 71% of patients who receive decitabine-plus-anti-PD-1 camrelizumab could achieve a complete response.
Full Text
Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission.
Full Text
Checkpoint inhibitors contribute to improving the treatment outcomes in patients with relapsed/refractory classical Hodgkin’s lymphoma (cHL).
Full Text
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress.
Full Text
BACKGROUND
Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Full Text
The checkpoint inhibitors nivolumab and pembrolizumab are principal treatment options for relapsed or refractory classic Hodgkin lymphoma.
Full Text
Concerning hematological malignancies, only nivolumab and pembrolizumab have been approved for the treatment of relapsed and refractory classical Hodgkin lymphoma and primary mediastinal large B cell lymphoma to date.
Full Text
BACKGROUND Academic studies have proved that anti-programmed death-1 (PD-1) monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma (cHL).
Full Text
We experienced three cases of chemotherapy-refractory classical Hodgkin lymphoma, those were treated by nivolumab as a salvage therapy and followingly received HLAhaploidentical HSCT.
Full Text
Checkpoint inhibitor pembrolizumab (KEYTRUDA), a chimeric antibody which targets programmed cell death protein 1 (PD-1), has been approved by the FDA for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma.
Full Text
Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor which has been approved for the treatment of recurrent or refractory classical Hodgkin lymphoma in China and have achieved improvement in a verity of solid tumors with manageable safety profile.
Full Text
It is used for the treatment of complicated or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy.
Full Text
BACKGROUND
PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma.
Full Text
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed or refractory classical Hodgkin lymphoma.
Full Text
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL).
Full Text
There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors.
Full Text
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda®) to submit evidence of its clinical and cost effectiveness for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (RRcHL) who did not respond to treatment with brentuximab vedotin.
Full Text
The management of relapsed and refractory classic Hodgkin lymphoma (HL) has changed substantially since the approval of brentuximab vedotin (BV) and the checkpoint inhibitors nivolumab and pembrolizumab.
Full Text
In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL).
Full Text
This issue of Leukemia and Lymphoma features an analysis of PROs from the KEYNOTE-087 trial, a phase 2 study of pembrolizumab in relapsed/refractory classical Hodgkin lymphoma [7].
Full Text
Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.
Full Text
We aimed to assess the activity and safety profile of sintilimab in Chinese patients with relapsed or refractory classical Hodgkin lymphoma.
Full Text
Introduction Microvascular decompression (MVD) is accepted as the only aetiological surgical treatment for refractory classic trigeminal neuralgia (TN).
Full Text
Clinical activity of brentuximab vedotin (BV), an antiCD30 antibody-drug conjugate, has been demonstrated in relapsed/refractory classical Hodgkin Lymphoma (R/R cHL) in pivotal phase I and phase II studies.
Full Text
We hypothesized that in relapsed/refractory classical Hodgkin lymphoma, CTC affects the ALC on the date of collection.
Full Text
Knowledge about the frequent NVC in asymptomatic individuals and its features is essential for interpreting preoperative MRI in patients with refractory classical TN considered for surgery.
Full Text
4% CR) in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
Full Text
Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision.
Full Text
KEYNOTE-087 and KEYNOTE204 are relapsed or refractory classic Hodgkin Lymphoma trials involving Pembrolizumab conducted at this study site.
Full Text
Case: 23 year old male with relapsed and refractory classical Hodgkin lymphoma underwent clinical trial with BV and Cyclosporin( CyA).
Full Text
The use of nivolumab in international clinical practice has significantly improved treatment results of patients with relapsed/refractory classical Hodgkin’s lymphoma.
Full Text